The sustained efficacy of GLP-1 RAs supports a paradigm shift in the clinical management of obesity, moving from short-term weight loss strategies to long-term pharmacotherapy for chronic disease control [16]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.